Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on June 2 announced longer-term follow up from its Phase 1 and pivotal Phase 2 trials of Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock opened today at $6.56 and is currently trading at $6.61. The stock showed a positive weekly performance of 2.83%.
Aegis reaffirmed their buy rating on shares of CytRx (NASDAQ:CYTR) in a report released on Monday. CytRx Corporation (NASDAQ:CYTR) stock opened at $4.41, in current trading session and currently is at $4.31, by losing -0.46%. The 52 week range of $1.95 – $8.35. Company’s market capitalization is 240.40 million.
Bristol-Myers Squibb Co (NYSE:BMY) and Syngene International, the research subsidiary of Biocon, the largest public-sector biotechnology company of India, announced that the two have extended the period of their drug development and discovery collaboration to five years. BMY did not reveal about the financial terms. Bristol-Myers Squibb Co (NYSE:BMY) stock is currently trading at $46.82. The EPS of the stock is 1.74. Company’s market capitalization is 77.59 billion.
Aspen Investment disclosed a 9.65% stake in VIVUS Inc. (NASDAQ:VVUS) and said it’s considering a $640 million purchase, which would be made definitive by June 13. VIVUS, Inc. (NASDAQ:VVUS) stock opened the session at $4.95, and now is at $4.93. The 52 week range of the VIVUS, Inc. (NASDAQ:VVUS) stock remained $4.56 – $15.40 and the day range was $4.87 – $4.99.
Celgene Corporation (NASDAQ:CELG) announced organizational changes that will go into effect on August 1, 2014. Celgene Corporation (NASDAQ:CELG) stock opened today at $160.00 and is currently trading at $158.52. The stock showed a positive weekly performance of 2.93%.